Genentech, Inc.
NEWS
Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.
The study assessed two doses of RG7716 versus ranibizumab standard of care given as monthly intravitreal injections.
Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein.
2017 was the second-best year for FDA approvals since 1996.
The fact that Roche has separate R&D units has been the topic of second-guessing on the part of observers and analysts.
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.
A look at the latest batch of FDA approvals this year.
A look at what three ex-Genentech employees have accomplished at Denali so far.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
JOBS
IN THE PRESS